Expert Panel's Recommendation
A panel of outside experts advising the US FDA stated that the benefits of Grail's blood-based cancer detection test outweigh its risks. This could potentially lead to a landmark approval in cancer screening.
The expert panel concluded, with a 7-2 vote and one abstention, that the Galleri test's capability to detect hard-to-find cancers justified its use in adults aged 50 and older.
Safety and Effectiveness
• The committee unanimously endorsed the test's safety.
• However, they were divided 6-4 on whether the evidence demonstrated its effectiveness.
FDA Decision and Test Details
The FDA is not bound by its panel's votes but considers them significantly. A final decision on national sales of Galleri is anticipated in the coming months.
Galleri Test Capabilities
• Galleri screens for multiple cancers from a single blood draw.
• It detects 35% of cancers within 12 months in a US study.
• The test boasts a 99.85% specificity.
Important Considerations
The committee stressed that doctors must clearly explain test limitations to patients, ensuring Galleri is an "addition, not substitution" to standard screenings like mammograms and colonoscopies.
Current Availability
1. Both Grail's Galleri and Abbott's Cancerguard are currently available under Clinical Laboratory Improvement Amendments regulations but are not yet FDA-approved.
टिप्पणियाँ
एक टिप्पणी भेजें